Chordate Medical Holding Investor Relations Material
Latest events
Q3 2024
Chordate Medical Holding
Q1 2025
23 May, 2025
Q4 2024
28 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Chordate Medical Holding
Access all reports
Chordate Medical Holding AB is a medical technology company that has developed and patented Ozilia Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The company focuses on providing solutions for patients suffering from chronic nasal congestion and chronic migraine, aiming to offer effective and non-pharmacological treatment options. The company is headquartered in Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CMH
Country
🇸🇪 Sweden